Chronic Liver Disease (CLD) Therapeutics Market in Middle East & Turkey is expected to be around US$1,500 Million with a healthy CAGR of 5.8% by 2028

Chronic liver disease is an extremely common disease. It is caused by a variety of factors, including a faulty gene that regulates iron absorption. He also has a range of symptoms, including elevated portal pressure and esophageal and gastric varices. The most serious complication of CLD is esophageal variceal bleeding, and other complications include ascites and cirrhosis.

Liver disease can be very painful and is often accompanied by other symptoms, including pain. If left untreated, this condition can cause scarring of the liver, preventing blood flow to other organs. It also forces the healthy parts of the liver to work harder. As a result, people with chronic liver disease may experience muscle weakness, itching, and weight loss, and may even develop kidney failure. Additionally, people with liver disease are at an increased risk of developing diabetes, hypertension, and high cholesterol.

The Chronic Liver Disease (CLD) Therapeutics Market in Middle East & Turkey is estimated at USD 1,015 Million in 2021 and is expected to grow at a CAGR of 5.8% over the forecast period (2022-2028). ).

Request the PDF brochure of this report here @ https://www.coherentmarketinsights.com/insight/request-pdf/4920

The increasing prevalence of chronic liver diseases such as non-alcoholic fatty liver disease, hepatitis and others among a large population base in the Middle East region due to lifestyle related diseases such as obesity and type 2 diabetes mellitus (DM) and this is expected to drive the demand for drugs used in the treatment of liver diseases, thereby propelling the growth of the market.

The chemotherapy drugs segment is expected to hold the largest market share in the Chronic Liver Disease (CLD) Therapeutics Market in Middle East & Turkey

Since cancer cells grow and multiply much faster than most cells in the body, chemotherapy is most often used for the treatment of cancer. The increasing incidence of liver cancer and the launch of new products for the treatment of cancer are some of the factors expected to drive the growth of the Chemotherapy Drugs segment. According to the International Agency for Research on Cancer (IARC), the age-standardized incidence rate (ASIR) of liver cancer was 4.5 per 100,000 people in 2018 in Saudi Arabia.

Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market Market Restriction

The high cost of chronic liver disease treatment is expected to hamper the market growth. Moreover, due to this factor, a large number of patients suffering from CLD cannot benefit from proper treatment. Treatment of chronic liver disease includes chemotherapy, targeted therapy, vaccines, immunoglobulin and others, which are too expensive for patients in low- and middle-income countries in MENA (Middle East and North Africa) . For example, the cost of surgical treatment for liver cancer at Herzliya Medical Center, Israel is 25,000 US dollars and the cost of chemotherapy starts at 3,500 US dollars.

Request here the sample copy of the report @ https://www.coherentmarketinsights.com/insight/request-sample/4920

Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of the Coronavirus (Covid-19) Pandemic

The coronavirus disease (COVID-19) outbreak was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19), World Health Organization Weekly Epidemiological Update, more than 263,563,622 cases and 5 232,562 deaths from coronavirus disease (COVID-19) have been reported through December 3, 2021 worldwide.

Cancer treatment options such as chemotherapy can weaken the immune system of cancer patients and increase the risk of infection. Therefore, people with cancer such as liver cancer are at higher risk of developing serious complications from COVID-19 infection.

Additionally, healthcare providers are adopting telehealth solutions to deliver their services to patients with severe chronic liver disease while maintaining social distancing to fight the COVID-19 pandemic without compromising the health of affected patients. of chronic liver disease. Patients can set up virtual appointments with their doctors for consultations. Healthcare providers are taking the above measures to reduce the spread of COVID-19 infection.

Additionally, some studies have also indicated that COVID-19 was significantly associated with alcoholic liver injury. Nevertheless, the impact of alcohol during COVID-19 on alcohol consumption and ALD may impact the pathogenesis of COVID-19.

Key players

Key players operating in Chronic Liver Disease (CLD) Therapeutics Market in Middle East & Turkey include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi SA, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc and Pfizer Inc. .

Buy this Premium Research Report directly, click here @ https://www.coherentmarketinsights.com/insight/buy-now/4920

Contents

Chapter 1 Industry overview
1.1 Definition
1.2 Assumptions
1.3 Scope of research
1.4 Market Analysis by Regions
1.5 Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market Industry Impact

Chapter 2 Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market Competition by Types, Applications, and Top Regions & Countries
2.1 Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market (Volume and Value) by Type
2.3 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market (Volume and Value) by Regions

chapter 3 Generation market analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures of Chronic Liver Disease (CLD) Therapeutics Market in Middle East & Turkey
Chapter 6 Middle East & Turkey Chronic Liver Disease (CLD) Therapeutics Market Forecast (2022-2028)
Chapter 7 conclusion
Research Methodology

About Us

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact us

Mr Shah
Consistent market information
1001 4th Avenue, #3200
Seattle, WA 98154
Phone: USA +12067016702 / UK +4402081334027
Email: [email protected]

Comments are closed.